Refractory heartburn to proton pump inhibitors: Epidemiology, etiology and management

Digestion

Volumn 73, Issue 4, 2006, Pages 218-227

  Sgouros, Spiros N ^a,b   Mantides, Apostolos ^a  

^a ATHENS NAVAL HOSPITAL   (Greece)

^b NONE   (Greece)

Author keywords

Functional heartburn; Gastroesophageal reflux disease; Hypersensitive esophagus; Proton pump inhibitors

Indexed keywords

4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; BACLOFEN; CITALOPRAM; CYTOCHROME P450 2C19; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; MESSENGER RNA; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ALGORITHM; BARRETT ESOPHAGUS; CONFUSION; DIZZINESS; DROWSINESS; DUODENOGASTRIC REFLUX; ERADICATION THERAPY; ESOPHAGOSCOPY; ESOPHAGUS PH; GASTRIC DYSMOTILITY; HEARTBURN; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; REVIEW; SYMPTOM; SYSTEMATIC REVIEW; TREMOR; WEAKNESS;

ENDOSCOPY, GASTROINTESTINAL; ENZYME INHIBITORS; GABA AGONISTS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMANS; INCIDENCE; MUSCLE RELAXANTS, CENTRAL; PROTON PUMPS; TREATMENT OUTCOME;

EID: 33749013839     PISSN: 00122823     EISSN: None     Source Type: Journal    
DOI: 10.1159/000094789     Document Type: Review

References (79)

1. Carlsson R, Dent J, Bolling-Sternevald E, et al: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998;33:1023-1029.
2. DeVault KR, Castell DO: Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005;100:190-200.
3. Havelund T, Lind T, Biklund I, et al: Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999;94:1782-1789.
4. Crawley JA, Schmitt CM: How satisfied are chronic heartburn sufferers with their prescription medications? Results of the patient unmet needs study. JCOM 2000;7:29-34.
5. McColl E, Junghard O, Wiklund I, Revicki DA: Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005;100:11-18.
6. Fass R, Sontag SJ, Traxler B, Sostek M: Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006;4:50-56.
7. Fass R, Murthy U, Hayden CW, et al: Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multicentre study. Aliment Pharmacol Ther 2000;14:1595-1603.
8. Inadomi JM, McIntyre L, Bernard L, Fendrick AM: Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completed relieved with PPIs. Am J Gastroenterol 2003;98:1940-1944.
9. Carlsson R, Dent J, Watts R, et al: Gastro-oesophageal reflux disease in primary care: an international study of 56 treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-124.
10. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R: Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664.
11. Lind T, Havelund T, Carlsson R, et al: Heart-burn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997;32:974-979.
12. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, et al: Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92:1997-2000.
13. Johnsson F, Weywadt L, Solhaug JH, et al: One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand J Gastroenterol 1997;33:15-20.
14. Fass R, Ofman JJ, Gralnek IM, et al: Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med 1999;159:2161-2168.
15. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537-545.
16. Clouse RE, Richter JE, Heading RC, Janssens J, Wilson JA: Functional esophageal disorders. Gut 1999;45(suppl 2):II31-II36.
17. Fass R, Tougas G: Functional heartburn: the stimulus, the pain and the brain. Gut 2002;51:885-892.
18. Watson RG, Tham TC, Johnston BT, McDougall NI: Double-blind cross-over placebo-controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux - the 'sensitive oesophagus'. Gut 1997;40:587-590.
19. Barlow WJ, Orlando RC: The pathogenesis of heartburn in non-erosive reflux disease: a unifying hypothesis. Gastroenterology 2005;128:771-778.
20. Richter JE, Bochenek W: Oral pantoprazole for erosive esophagitis: a placebo-controlled randomized clinical trial. Pantoprazole US GERD Study Group. Am J Gastroenterol 2000;95:3071-3080.
21. Castell DO, Kahrilas PJ, Richter JE, et al: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-583.
22. Castell DO, Richter JE, Robinson M, Sontag SJ, Haber MM: Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol 1996;91:1749-1757.
23. Sharma VK, Leontiadis GI, Howden CW: Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. Aliment Pharmacol Ther 2001;15:227-231.
24. Miner P: Review article: relief of symptoms in gastric acid-related diseases - correlation with acid suppression in rabeprazole treatment. Aliment Pharmacol Ther 2004;20(suppl 6):20-29.
25. Katzka DA, Castell DO: Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1994;89:989-991.
26. Ouatu-Lascar R, Triadafilopoulos G: Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's oesophagus. Am J Gastroenterol 1998;93:711-716.
27. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G: Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999;117:327-335.
28. Fass R, Sampliner RE, Malagon IB, et al: Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000;14:597-602.
29. Sampliner RE: Effect of up to 3 years of high-dose lansoprazole on Barrett's oesophagus. Am J Gastroenterol 1994;89:1844-1848.
30. Malesci A, Savarino V, Zentilin P, et al: Partial regression of Barrett's oesophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-705.
31. The Gallup Organization: Gallup Study of Consumers' Use of Stomach Relief Products. Princeton/NJ, The Gallup Organization, 2000.
32. Kuo B, Castell DO: Optimal dosing of omeprazole 40 mg daily: effects on gastric and esophageal pH and serum gastrin in healthy controls. Am J Gastroenterol 1996;91:1532-1538.
33. Hatlebakk JG, Katz PO, Kuo B, et al: Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
34. Diener U, Patti MG, Molena D, et al: Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg 2001;5:560-565.
35. Kudara N, Chiba T, Orii S, Suzuki K: Gastric emptying of patients with persistent reflux symptoms and erosive esophagitis under PPI therapy (abstract). Neurogastroenterol Motil 2004;16:654.
36. Tack J, Koek G, Demedts I, Sifrim D, Janssens J: Gastro-oesophageal reflux disease poorly responsive to single-dose proton pump inhibitors in patients without Barrett's oesophagus: acid reflux, bile reflux, or both? Am J Gastroenterol 2004;99:981-988.
37. Sgouros SN, Bergele C, Mantides A: Eosinophilic esophagitis in adults: a systematic review. Eur J Gastroenterol Hepatol 2006;18:211-217.
38. Sgouros SN, Mantides A: Proton pump inhibitor failure in gastro-oesophageal reflux disease - what about eosinophilic oesophagitis? Aliment Pharmacol Ther 2006;23:1281-1283.
39. Sgouros SN, Bergele C, Mantides A: Eosinophilic esophagitis in adults: what is the clinical significance? Endoscopy 2006;38:515-520.
40. Vela M, Camacho-Lobato L, Srinivasan R, Tutuian R, Katz PO, Castell DO: Simultaneous intraesophageal impedance and pH measurement of acid and non-acid gastrooesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599-1606.
41. Shay S, Sifrim D, Tutuian R, Zhang X, Vela M, Castell DO: Multichannel intraluminal impedance in the evaluation of patients with persistent GERD symptoms despite proton pump inhibitors: a multicenter study (abstract). Gastroenterology 2003;124:A537 (No T1633).
42. Verdu EF, Armstrong D, Fraser R, et al: Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-543.
43. +-ATPaSe α-subunit gene expression by Helicobacter pylori. Am J Physiol Gastrointest Liver Physiol 2000;278:G981-G991.
44. +-adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa. Gut 2006;55:152-157.
45. Holtmann G, Cain C, Malfertheiner P: Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11-16.
46. Peghini PL, Katz PO, Bracy NA, Castell DO: Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol 1998;93:763-767.
47. Fouad YM, Katz PO, Castell DO: Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. Aliment Pharmacol Ther 1999;13:1467-1471.
48. 2 blockade at bedtime in the suppression of nocturnal oesophageal and gastric acidity. Aliment Pharmacol Ther 2003;17:1553-1558.
49. Nzeako UC, Murray JA: An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. Aliment Pharmacol Ther 2002;16:1309-1316.
50. 2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-632.
51. Leite L, Lambrecht N, Sachs G, Castell DO, Langerström P: Is omeprazole resistance due to mutations of cysteine 813 or 822 in the acid pump (abstract). Gastroenterology 1995;108:A147.
52. Caraco Y, Wilkinson GR, Wood AJ: Differences between white subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996;60:396-404.
53. Furuta T, Shirai N, Watanabe F, et al: Effect of cytochrome P4502C19 genotypic differences on cure rates for gastro-oesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002;72:453-460.
54. Kawamura M, Ohara S, Koike T, et al: The effect of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003;17:965-973.
55. Egan LJ, Myhre GM, Mays DC, Dierkhising RA, Kammer PP, Murray JA: CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment Pharmacol Ther 2003;17:1521-1518.
56. Loftus CG, Harewood GC, Romero Y, Cameron AJ, Murray JA: Declining diagnostic utility of upper endoscopy in patients with gastro-oesophageal reflux disease (abstract). Gastrointest Endosc 2002;55:AB89 (No 459).
57. Kahrilas PJ, Quigley EM: Clinical esophageal pH recording: a technical review for practice guideline development. Gastroenterology 1996;110:1982-1996.
58. Vaezi MF, Richter JE, Stasney ER, et al: A randomized, double-blind, placebo-controlled study of acid suppression for the treatment of suspected laryngopharyngeal reflux (abstract). Gastroenterology 2004;126:A22 (No 160).
59. Olden K, Triadafilopoulos G: Failure of initial 24-hour esophageal PH monitoring to predict refractoriness and intractability in reflux esophagitis. Am J Gastroenterol 1991;86:1141-1146.
60. Wiener GJ, Morgan TM, Copper JB, et al: Ambulatory 24-hour esophageal pH monitoring. Reproducibility and variability of pH parameters. Dig Dis Sci 1988;33:1127-1133.
61. Shi G, Bruley des Varannes S, Scarpignato C, et al: Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457-464.
62. Ghillebert G, Demeyere AM, Janssens J, et al: How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease. Dig Dis Sci 1995;40:1317-1324.
63. Quigley EMM: 24-h pH monitoring for gastroesophageal reflux disease: already standard but not get gold. Am J Gastroenterol 1992;87:1071-1075.
64. Sgouros SN, Vlachogiannakos J, Karamanolis G, et al: Long-term acid suppressive therapy may prevent the relapse of lower esophageal (Schatzki's) rings; a prospective, randomized, placebo-controlled study. Am J Gastroenterol 2005;100:1929-1934.
65. Franzen T, Tibbling Grahn L: Reliability of 24-hour oesophageal pH monitoring under standardized conditions. Scand J Gastroenterol 2002;37:6-8.
66. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas PJ: Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003;98:740-749.
67. Pandolfino JE, Schreiner MA, Lee TJ, et al: Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol 2005;100:1466-1476.
68. Pandolfino J, Zhang Q, Schreiner M, et al: Acid reflux event detection using the Bravo™ wireless vs. the Slimline™ catheter pH systems: why are the numbers so different? Gut 2005;54:1687-1692.
69. Bruley des Varannes S, Mion F, Ducrotte P, et al: Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo®). Gut 2005;54:1682-1686.
70. B agonist baclofen in patients with symptoms and duodeno-gastro- oesophageal reflux refractory to proton pump inhibitors. Gut 2003;52:1397-1402.
71. Kahrilas PJ, Quigley EM, Castell DO, Spechler SJ: The effects of tegaserod (HTF 919) on oesophageal acid exposure in gastrooesophageal reflux disease. Aliment Pharmacol Ther 2000;14:1503-1509.
72. Broekaert D, Fischler B, Sirfrim D, Janssens J, Tack J: Influence of citalopram, a selective serotonin reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2006;23:365-370.
73. Clouse RE: Psychotropic medications for the treatment of functional gastrointestinal disorders. Clin Perspect Gastroenterol 1999;2:348-356.
74. Varia I, Logue E, O'Connor C, et al: Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J 2000;140:367-372.
75. Prakash C, Clouse RE: Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999;44:2373-2379.
76. So JB, Zeitels SM, Rattner DW: Outcomes of atypical symptoms attributed to gastro-oesophageal reflux treated by laparoscopic fundoplication. Surgery 1998;124:28-32.
77. Chuttani R, Sud R, Sachdev G, et al: A novel endoscopic full-thickness plicator for the treatment of GERD: a pilot study. Gastrointest Endosc 2003;58:770-776.
78. Triadafilopoulos G, Dibaise JK, Nostrant TT, et al: Radiofrequency energy delivery to the gastroesophageal function for the treatment of GERD. Gastrointest Endosc 2001;53:4.
79. Feretis C, Benakis P, Dimopoulos C, et al: Endoscopic implantation of Plexiglas (PMMA) microspheres for the treatment of GERD. Gastrointest Endosc 2001;53:423-426.